All In Biotech

NDA 019680 · Abbvie

Depakote

Divalproex Sodium · Oral

Last checked: Nov 20, 2026Latest source record: Mar 31, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1989

Sep 12, 1989

Approved uses

3

Original approval plus efficacy supplements

Registered trials

398

85 Phase 3, 16 recruiting

FAERS reports

42,540

29,035 serious, 2,388 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: LIFE THREATENING ADVERSE REACTIONS Hepatotoxicity General Population: Hepatic failure resulting in fatalities has occurred in patients receiving valproate and its derivatives. These incidents usually have occurred during the first six months of treatment. Serious or fatal hepatotoxicity may be preceded by non-specific symptoms such as malaise, weakness, lethargy, facial edema, anorexia, and vomiting. In patients with epilepsy, a loss of seizure control may also occur. Patients should be monitored closely for appearance of these symptoms. Serum liver tests should be performed prior to therapy and at frequent intervals thereafter, especially during the first six months [see Warnings and Precautions ( 5.1 )] . Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with...

What it is approved for

From the label in effect Mar 31, 2026.

Depakote Sprinkle Capsules are an anti-epileptic drug indicated for: Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1 ) 1.1 Epilepsy Depakote Sprinkle Capsules are indicated as monotherapy and adjunctive therapy in the treatment of adult patients and pediatric patients down to the age of 10 years with complex partial seizures that occur either in isolation or in association with other types of seizures. Depakote Sprinkle Capsules are also indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types that include absence seizures. Simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. Complex absence is the term used when other signs are also present. 1.2 Important Limitations Because of the risk to the fetus of decreased IQ, neurodevelopmental disorders, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be used to treat women with epilepsy or bipolar disorder who are pregnant or who plan to become pregnant unless other medications have failed to provide adequate symptom control or are otherwise unacceptable. Valproate should not be administered to a woman of childbearing potential unless other medications have failed to provide adequate symptom control or are otherwise unacceptable [see Warnings and Precautions ( 5.2 , 5.3 , 5.4 ) , Use in Specific Populations ( 8.1 ) , and Patient Counseling Information ( 17 ) ] . For...

Mechanism: Divalproex sodium dissociates to the valproate ion in the gastrointestinal tract. The mechanisms by which valproate exerts its therapeutic effects have not been established. It has been suggested that its activity in epilepsy is related to increased brain concentrations of gamma-aminobutyric acid (GABA).

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 24, 2008 Supplement 24 · Efficacy · priority review
  • Jun 20, 1996 Supplement 8 · Efficacy
  • Sep 12, 1989 Original approval · Type 3 - New Dosage Form Other Important Information from FDA
1 products under this application
  • DEPAKOTE · DIVALPROEX SODIUM EQ 125MG VALPROIC ACID · CAPSULE, DELAYED REL PELLETS, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Divalproex" as an intervention, any sponsor and status, largest first.

All 398 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective2,910
  • seizure2,465
  • weight increased1,996
  • off label use1,989
  • nausea1,960
  • fatigue1,819
  • pain1,809
  • somnolence1,753
  • tremor1,643
  • fall1,640
  • anxiety1,604
  • vomiting1,537

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,146
20051,255
20061,190
20071,179
20081,195
20092,479
20102,155
20112,052
20122,043
20131,760
20141,854
20152,475
20162,644
20172,205
20182,092
20192,129
20201,907
20211,991
20222,047
20231,770
20241,783
20251,875
20261,309

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Depakote (Divalproex Sodium)

2024 spending

$11.9M

Beneficiaries

2,352

15,783 claims

Per beneficiary

$5,045

$5.19 per unit

View as table
YearSpending
2020$15,805,669
2021$14,495,591
2022$13,496,837
2023$12,924,238
2024$11,865,909

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 305 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.